1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Nevro Corp.
  6. News
  7. Summary
    NVRO   US64157F1030

NEVRO CORP.

(NVRO)
  Report
Delayed Nyse  -  04:00 2022-08-12 pm EDT
51.69 USD   +1.55%
08/10NEVRO : Canaccord Genuity Annual Growth Conference Presentation
PU
08/09Nevro Announces Participation In Upcoming Investor Conferences
PR
08/04Wells Fargo Securities Adjusts Nevro's Price Target to $86 From $90, Reiterates Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nevro : to Report Third Quarter 2021 Financial Results

10/11/2021 | 06:01am EDT

REDWOOD CITY, Calif., Oct. 11, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the third quarter ended September 30, 2021 after the market closes on November 8, 2021.

Management will host a conference call on November 8, 2021 to discuss third quarter 2021 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (866) 324-3683 in the U.S. or +1 (509) 844-0959 internationally, using Conference ID: 8987949. A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com.  The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain.  Nevro's proprietary 10 kHz Therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies.  The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy. 

SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, HFX, the HFX logo, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corp Communications
650-433-3247  |  julie.dewey@nevro.com

.

 

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-to-report-third-quarter-2021-financial-results-301391814.html

SOURCE Nevro Corp.


© PRNewswire 2021
All news about NEVRO CORP.
08/10NEVRO : Canaccord Genuity Annual Growth Conference Presentation
PU
08/09Nevro Announces Participation In Upcoming Investor Conferences
PR
08/04Wells Fargo Securities Adjusts Nevro's Price Target to $86 From $90, Reiterates Overwei..
MT
08/04Piper Sandler Adjusts Nevro's Price Target to $45 From $64, Maintains Neutral Rating
MT
08/03NEVRO : Q2 Earnings Snapshot
AQ
08/03NEVRO : Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidanc..
PU
08/03NEVRO CORP Management's Discussion and Analysis of Financial Condition and Results of ..
AQ
08/03Nevro Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 3..
CI
08/03NEVRO : Second Quarter 2022 Earnings Presentation
PU
08/03Earnings Flash (NVRO) NEVRO Posts Q2 Revenue $104.2M
MT
More news
Analyst Recommendations on NEVRO CORP.
More recommendations